Bumrungrad Hospital Public Company Limited

DB:BZ7A Stock Report

Market Cap: €4.3b

Bumrungrad Hospital Valuation

Is BZ7A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BZ7A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€7.23
Fair Value
27.4% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: BZ7A (€5.25) is trading below our estimate of fair value (€7.23)

Significantly Below Fair Value: BZ7A is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BZ7A?

Key metric: As BZ7A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BZ7A. This is calculated by dividing BZ7A's market cap by their current earnings.
What is BZ7A's PE Ratio?
PE Ratio20.4x
Earnings฿7.59b
Market Cap฿155.01b

Price to Earnings Ratio vs Peers

How does BZ7A's PE Ratio compare to its peers?

The above table shows the PE ratio for BZ7A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.4x
RHK RHÖN-KLINIKUM
23.1x7.5%€1.0b
M12 M1 Kliniken
17.2x16.0%€287.6m
LIK LIMES Schlosskliniken
23xn/a€98.5m
AFX Carl Zeiss Meditec
22.3x15.7%€4.0b
BZ7A Bumrungrad Hospital
20.4x3.2%€155.0b

Price-To-Earnings vs Peers: BZ7A is good value based on its Price-To-Earnings Ratio (20.4x) compared to the peer average (21.4x).


Price to Earnings Ratio vs Industry

How does BZ7A's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BZ7A 20.4xIndustry Avg. 18.8xNo. of Companies8PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BZ7A is expensive based on its Price-To-Earnings Ratio (20.4x) compared to the European Healthcare industry average (18.6x).


Price to Earnings Ratio vs Fair Ratio

What is BZ7A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BZ7A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.4x
Fair PE Ratio19.8x

Price-To-Earnings vs Fair Ratio: BZ7A is expensive based on its Price-To-Earnings Ratio (20.4x) compared to the estimated Fair Price-To-Earnings Ratio (19.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 21 Analysts
€7.38
Fair Value
28.9% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:24
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bumrungrad Hospital Public Company Limited is covered by 50 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kawee ManitsupavongAsia Plus Securities Company Limited
Weiyee InBNP Paribas Securities (Asia)
Chutima WoramontriBNP Paribas Securities (Asia)